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CHAPTER 1
COMPLEMENT ACTIVATION TRIGGERS METALLOPROTEINASES RELEASE
INDUCING CERVICAL REMODELING AND PRETERM BIRTH IN MICE
Introduction
Successful parturition in mammalian species is characterized by two essential
processes. First, the myometrium changes from a quiescent to a highly contractile
state. Second, the uterine cervix undergoes a substantial remodeling process, during
which a closed, rigid cervix turns into a distensible and elastic ring that stretches to
allow passage of the fetus. Then, the cervix undergoes rapid repair in order to ensure
protection of the reproductive tract from microbial infection. Appropriate and timely
cervical remodeling is essential for successful birth. Premature cervical remodeling,
which results in dilation and effacement of the cervix, can lead to preterm birth, a
leading cause of perinatal mortality and morbidity. Premature birth/delivery (PTD) is
one of the most significant causes of perinatal mortality and morbidity in developed
countries.

Preterm

infants

suffer

morbidities

including

respiratory

distress,

intraventricular hemorrhage, and cerebral palsy, among other serious diseases.1 These
outcomes can have a life-long impact and more than $25 billion is spent each year to
take care of these infants.

Investigations to define the causes of PTD remain a

challenge in the obstetrical field. Preterm labor is a multistage biochemical and
biophysical process, during which changes in the myometrium and the cervix occur.
The uterine cervix is a complex organ that undergoes extensive changes through
gestation and parturition.

These changes are a common first step in preterm

parturition.2 As a gatekeeper for pregnancy, the cervix is a structural barrier that keeps
the fetus inside the uterus until the end of gestation. Collagens, elastin, proteoglycans,
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and hyaluronate are responsible for the full tensile strength of the cervix.2 Ripening of
the cervix is an important biological and clinical event required for a normal parturition.
The process is gradual during pregnancy, with a fast final remodeling of the cervix
before parturition. Increased collagen degradation and synthesis, and high activity of
collagenases have been observed in the human cervix during final ripening.3
Improper timing of these complex changes can result in PTD, which is a major
public health problem, and there has been little reduction in its incidence during the past
40 years.4,5 This is mainly caused by our incomplete understanding of the cascade and
processes that occur in the remodeling of the cervix.

The characterization of the

cervical changes that precede parturition in women is complicated, because it is difficult
to determine antenatally which women will deliver preterm. Therefore, an animal model
that best simulates the clinical scenarios can be used to investigate the mechanisms
underlying cervical remodeling and PTD.6
Inflammation and activation of innate immunity has been associated with preterm
delivery.7 Recently, a study demonstrated that inflammatory cytokines in cervicovaginal
fluid and in amniotic fluid, but not in plasma, are strongly associated with spontaneous
PTD in women, suggesting that inflammation at the maternal-fetal interface, rather than
systemic inflammation, may play a major role in the etiology of PTD.8 Despite the
growing association between inflammation and PTD, the mediators, receptors, and
cellular participants in triggering cervical changes remain unclear. Therefore, we sought
to study the mechanism or mechanisms responsible for the cervical changes underlying
PTD induced by localized inflammation in mice. In this study, we induced PTD in mice
by intravaginal administration of lipopolysaccharide (LPS), resembling ascending
infection/inflammation, which is the most common clinical situation. We also used a
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second mouse model of preterm parturition induced by progesterone antagonist RU486.
Progesterone antagonists have been previously shown to cause infiltration of
inflammatory cells into the cervical stroma in pregnant mice and women.9,10
The complement system, an important component of innate immunity, plays a
pivotal role in recruiting inflammatory and immunocompetent cells contributing to
various immune and inflammatory diseases.

Several complications of pregnancy,

including spontaneous pregnancy losses,11,12 pre-eclampsia,13,14 and pre-term labor15-21
have been associated with a maternal complement activation. Importantly, complement
activation initiated by the alternative pathway has been associated with preterm labor
and delivery, but not labor at term.20 Importantly, increased activation of complement
components in maternal blood and the amniotic fluid has been reported in patients with
preterm delivery.15,16,19

Thus, we hypothesized that complement activation is a

mediator in inflammation-induced preterm delivery in mice. The objective of the present
study was to test the hypothesis that complement activation may account for the
cervical changes responsible for inflammation-induced PTD in mice.
It has been reported that progesterone can reduce the rate of PTD in a high-risk
population.22-31

The biological mechanisms responsible for the protective effect of

progesterone remain poorly elucidated. In addition, progesterone has been suggested
to have anti-inflammatory effects,32,33 and mice lacking progesterone receptor exhibit
reproductive abnormalities characterized by inflammation.34 Therefore, we sought to
investigate if progesterone is able to decrease or prevent inflammation-induced PTD in
mice.

Identifying the immune effectors that mediate PTD might provide novel and

important targets for the prevention and prediction of premature labor in women.
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Materials and Methods
Ethics Statement
Our animal studies were performed by following the Russell and Burch “Three
R's” concept of Replacement, Reduction, and Refinement to minimize animal use and
pain or distress while still achieving the critical scientific objectives.

All of the

experiments performed were conducted in accordance with the National Institute of
Health guidelines on laboratory animals and with approval from Wayne State University
(protocol A 09-08-09) and York College, The City University of New York (protocol R-32009) committee on Animal Use and Care.
Animals
C57BL/6 timed-pregnant mice were purchased from Jackson Laboratories (Bar
Harbor, ME).

Animals were shipped on days 10 to 12 after mating. Animals were

acclimated in the animal facility for 3 to 5 days before use in these experiments. C5aRdeficient (C5aR−/−) females and males were also purchased from Jackson
Laboratories. C5aR−/− females were mated with C5aR−/− males in our animal facility.
The presence of a vaginal plug was considered as day 0 of pregnancy.
Mouse Models of Preterm Delivery
PTD Induced by LPS
In an attempt to develop a mouse model of PTD, which resembles most clinical
scenarios in that localized inflammation occurs without systemic maternal illness, we
administered LPS (Escherichia coli serotype 055:B5 (250 μg/mouse, intravaginally) on
day 15 of pregnancy.

This model mimics a clinical or subclinical vaginal

infection/inflammation that can ascend to the cervix, the deciduas, myometrium, fetal
membranes, the amniotic fluid, and thus the fetus leading to premature labor. Most of
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the pregnant females (94.7%) delivered within 24 to 36 hours of LPS administration
(Figure 1A). No maternal morbidity or mortality was observed in this model.
To determine whether supplementation with progesterone could prevent
inflammation-induced preterm parturition, on day 15 of pregnancy the mice were
randomly treated with progesterone (2 mg/mouse, s.c.; Sigma Chemicals, St Louis, MO)
(n = 14) or an equal volume of vehicle (sunflower oil) (n = 5) 1 hour before LPS
administration.
To elucidate the role of complement receptor C5a (C5aR), C5aR−/− mice (n = 9)
received intravaginal LPS on day 15 of pregnancy.
To deplete macrophages 300 μg of anti-F4/80 (BM8; eBioscience) or isotype
antibody (rat IgG2a, κ; eBioscience, San Diego, CA) was given i.p. on day 15, 4 hours
before LPS injection (n = 4 to 6). This antibody was previously used successfully to
deplete macrophages in pregnant mice.35
Mice from every experimental group were euthanized antepartum (12 to 18 hours
after treatment) (n = 5 to 7 mice/group). Blood samples and cervical tissue were
collected from the mice in each experimental group. Macroscopic, biomechanical, and
histological evaluation of the cervix was performed. Delivery was considered preterm if
it occurred within 48 hours after LPS administration (before gestational day 17).
PTD Induced by Progesterone Antagonist RU486
In this model, PTD was induced by administration of RU486 (mifepristone, Sigma
Chemicals, St. Louis, MO) (150 μg/mouse subcutaneously) (n = 6) dissolved in dimethyl
sulfoxide, as described in the literature.36

It was previously described that RU486

increases the recruitment of immune cells to the cervix.9,10 Mice treated with RU486
give birth within 24 hours (Figure 1A). Mice were euthanized during the antepartum (12

6
to 18 hours after treatment) to analyze the cervical changes that precede PTD.
Gestational age-matched controls were euthanized at the same time as treated mice.
Delivery was considered preterm if it occurred within 48 hours after RU486
administration (before gestational day 17).
To study the role of C5aR, C5aR−/− mice (n = 7) were treated with RU486 on
day 15 as previously described. Mice from every experimental group were euthanized
antepartum (12 to 18 hours after treatment). Gestational age-matched controls were
euthanized at the same time as treated mice. Blood samples and cervical tissue were
collected from mice in each experimental group. Macroscopic, biomechanical, and
histological evaluation of the cervix was performed.
Serum C3adesArg and C5adesArg Levels
To determine whether complement activation occurs in LPS and RU486-treated
mice that deliver preterm, generation of complement split products C3a and C5a were
measured by the more stable metabolites C3adesArg and C5adesArg. The C3adesArg
in serum was measured by sandwich enzyme-linked immunosorbent assay (ELISA)
using rat anti-mouse C3a and biotin rat anti-mouse C3a.

Both antibodies were

purchased from BD Biosciences Pharmingen (San Diego, CA). A Standard curve was
performed using purified mouse C3a protein (native) (BD Biosciences Pharmingen).
C5adesArg was also measured by sandwich ELISA using rat anti-mouse C5a and biotin
rat anti-mouse C5a. Both antibodies and mouse purified C5a protein for the standard
curve were purchased from BD Biosciences.
To determine whether LPS treatment diminished progesterone levels in mice,
antepartum serum progesterone was measured by Enzyme Immune assay (Cayman
Chemicals, Ann Arbor, MI).
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Tissue Biomechanics
The stiffness of the cervix was evaluated by measuring the elastic modulus. The
cervix were excised longitudinally and mounted to tensile testing equipment with a
calibrated mechanical drive attached to a force transducer (Com-Ten, Pinellas Park,
FL). The length of the cervix was increased isometrically in 10-mm increments per
minute. The amount of force required to distend the cervix and the tension exerted by
the stretched tissue were recorded.

The length was increased until either forces

exerted by the tissue reached a plateau or the tissue tore. Force was plotted as a
function of cervical length. The slope of the linear portion of the force-strain curve was
computed as an index of tissue stiffness and elasticity (elastic modulus). A steeper
slope indicates increased resistance to stretch, and therefore decreased elasticity
(elastic modulus). The data were recorded using data acquisition Com-Ten software.
Immunohistochemistry and Immunocytochemistry
For immunohistochemical studies, cervical tissues were frozen in OCT
compound, and cut into 10-μm sections. These sections were stained for C3 with rabbit
anti-mouse C3 (2 μg/mL; LifeSpan Biosciences, Seattle, WA), neutrophils were stained
with rat anti-mouse granulocyte RB6-8C5 mAb (5 μg/mL; BD Biosciences Pharmingen),
and macrophages were stained with F4/80 (10 μg/mL; Novus Biologicals Inc, Littleton,
CO). Matrix metalloproteinase (MMP)-9 was detected in frozen cervical sections using
a rabbit polyclonal anti-mouse MMP-9 antibody (10 μg/mL; Abcam, Cambridge, MA).
MMP-2 was detected in using a rabbit polyclonal anti-mouse MMP-2 antibody (3 μg/mL;
Abcam, Cambridge, MA). Collagen I distribution was determined using a polyclonal
antibody against collagen type I (10 μg/mL; ACRIS Antibodies, GmbH, Herford,
Germany).

Horseradish peroxidase-labeled specific secondary antibodies and 3,3′-
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diaminobenzidine as substrate were used to develop the respective reactions.
Masson's Trichrome staining was also performed to detect collagen fibers
distribution in cervical frozen sections.

The collagen fibers stained blue and the

background stained red. Four slides per animal were stained and 6 to 8 animals were
studied in each experimental group.
In situ Zymography
MMP-9 activity and MMP-2 activity were measured by in situ zymography as
previously described.37 Briefly, 10-μm-cervix sections were washed in PBS and then
incubated for 2 hours in 20 μg/mL DQ-labeled gelatin, DQ-collagen I, or DQ collagen IV
(Invitrogen, Carlsbad, CA) in 50 mmol/L Tris-HCl, 50 mmol/L NaCl, 10 mmol/L CaCl2,
pH 6.8 at 37°C in the dark. In parallel, control sections were pre-incubated with buffer
containing 10 mmol/L EDTA followed by 2-hour incubation in DQ-gelatin or DQ-collagen
solution supplemented with 10 mmol/L EDTA to indicate the contribution of
metalloproteinases.

The reaction was stopped by removing the substrate solution

followed by 10 minutes incubation in 4% paraformaldehyde PBS. Finally, mounting
medium supplemented with DAPI (Vector Laboratories, Burlingame, CA) was applied.
Sections were observed under a fluorescence microscope (Nikon Eclipse 50i; Nikon
Inc., Melville, NY) and photographs were taken using a Nikon DigiSight Color Digital
Camera System and NIS-Elements Research Imaging Software.

Increased

fluorescence indicates increased gelatin and collagen degradation by MMPs.

Each

experimental group consisted of 6 to 9 mice and four tissue sections per animal were
studied.
Preparation of Cervical Tissue Lysates for Gelatin Zymography
Cervical tissues were dissected immediately after euthanasia, and 1 g of tissue
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was homogenized in 1 mL of lysis buffer consisting of 0.1 M Tris-HCl, pH 6.8, 1 M urea,
1% nonyl phenoxypolyethoxylethanol (NP)-40, 10 mmol/L EDTA, 1 mmol/L 4-(2aminoethyl) benzenesulfonyl fluoride (AEBSF), and proteinase-inhibitor mix, using a
homogenizer. All lysates were centrifuged at 15,000 g for 30 minutes, and colorimetric
protein detection was performed in the supernatants using the BCATM Protein assay kit
(Pierce, Rockford, IL).

Samples of equal protein content (25 μg) were mixed with

fivefold concentrated Laemmli buffer separated by electrophoresis on 10% SDSpolyacrylamide gels containing 0.8 mg/mL gelatin in a nonreducing condition. After
electrophoresis, the gel was rinsed twice for 10 minutes in 2.5% Triton-X-100 to wash
off the SDS and rinsed twice for 10 minutes in water to remove Triton-X-100. The gel
was then incubated with an incubation buffer containing 1% Tween 20, 10 mmol CaCl2,
1 μmol ZnCl2, and 50 mmol Tris-Cl (pH 7.5) at 37°C for 18 hours, and stained with BioSafe Coomassie Stain solution (Bio-Rad, Hercules, CA). Purified Pro-MMP-9 (R&D
Systems, Minneapolis, MN) was used for identification. Three independent experiments
with different mice were performed.
Production of MMP-9 Proenzyme in vitro
Splenocytes from C57BL/6 female mice were incubated for 12 and 24 hours in
culture medium supplemented with 10% inactivated fetal bovine serum. Nonadherent
cells were removed and adherent cells (>95% peroxidase-positive) were incubated in
culture medium supplemented with 10% inactivated fetal bovine serum, with the
addition of the following stimuli: none (control); C5a (10 nmol/L); C5a (10 nmol/L) plus
progesterone (10 nmol/L). After 12 and 24 hours, culture supernatants were collected
and analyzed for MMP-9 proenzyme by ELISA (R&D Systems).
A group of macrophages was incubated on slides with increasing concentrations
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of progesterone (10, 20, and 40 nmol/L). After 12 hours incubation, macrophages were
tested for C5aR synthesis by RT-PCR and expression by IHC. For IHC, cells were fixed
in 5% paraformaldehyde and stained with anti-C5aR antibody (20 μg/mL Hycult Biotech;
Cell Sciences Inc., Canton, MA) followed by secondary antibody labeled with
horseradish peroxidase. Some macrophages were permeabilized before staining with
Tween 20 (0.5%).

The histochemical reaction was developed with DAB. The DAB

staining was quantified using the NIS-Elements Research Imaging software (Nikon Inc.
Tech Co., Ltd., Tokyo, Japan). Exposure time was fixed and the camera settings were
kept constant. The macrophages were segmented based on red/green/blue intensity,
and the area was restricted to eliminate debris. Measurements data per object were
calculated using the following parameters: sum density (the sum of individual optical
densities of each pixel in the area being measured) and mean density (statistical mean
of density values of pixels). NIS-Elements BR (Nikon Inc., Tokyo, Japan) uses density
calibration curves for evaluation of these parameters. There were 25 macrophages per
slide that were analyzed in each experimental condition.
Quantitative RT-PCR
To determine whether C5a differentially regulated the expression of MMP-9 in
macrophages, we studied the synthesis of MMP-9.

RNA was harvested from

macrophages with RNeasy Mini Kit (Qiagen, Valencia, CA) and 1 μg of total RNA was
reverse transcribed. Relative quantification of gene expression was performed by realtime PCR using The Biomark System (Fluidigm San Francisco, CA). Primer sequences
mouse glyceraldehydes-3-phosphate dehydrogenase and mouse MMP-9 were obtained
from Applied Biosystems (Foster City, CA). Relative expression was normalized for
levels of GAPDH. The generation of only the correct size amplification products was
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confirmed using agarose gel electrophoresis.
To investigate the effects of progesterone on C5aR expression in macrophages,
we also performed qRT-PCR as previously described. The primers for C5aR were also
obtained from Applied Biosystems (Foster City, CA).
Statistical Analysis
Data are expressed as mean ± SD. After confirming that the data were normally
distributed (Kolomogorov-Smirnov test of normalcy), statistical analyses were
conducted using Student's t-test to compare differences in means. Associations were
considered to be statistically significant if the value of P < 0.05. Data were processed
using SigmaStat (version 3.1), statistical program for Windows.
Results
Collagen Degradation in Cervical Remodeling Induced by LPS and RU486
Mice treated with LPS or RU486 delivered preterm. Parturition in these mice
occurred before gestational day 17 (Figure 1A).

To elucidate the mechanism

responsible for PTD, we investigated if remodeling of the cervix occurs in these mice.
Collagen I and III are the predominant component of the cervix extracellular
matrix and gives tensile strength to it.2,38 Collagenases of the MMP family degrade
collagen softening of the cervix (in a process called cervical remodeling) and prepare it
for dilation and delivery.3 Macroscopic examination of the cervix in LPS- and RU486–
treated mice (Figure 1B) antepartum showed increased distensibility and elasticity when
compared to firm and rigid cervix observed in gestational age match controls (Figure
1B, left panel). Biomechanical studies of the cervix confirmed these results. The slope
of the ascendant part of the regression line of the stress-strain curve (elastic modulus)
was decreased in the cervical tissue of LPS- and RU486-treated mice when compared
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Figure 1. Cervical remodeling and preterm labor/delivery (PTD) in LPS- and RU486-mice. A:
Delivery time in control and LPS- or RU486-treated mice (n = 5 to 7 mice/group). Significantly different
from control, *P < 0.05. B: Gross evaluation of the cervix. Arrows identify the posterior side of the cervix.
Note the increased distensibility observed in LPS- (middle panel) and RU486-treated mice (right panel)
when compared to the firm and rigid cervix of control mice (left panel). C: Biomechanical studies of the
cervix. The elastic modulus was decreased in the cervical tissue of LPS- and RU486-treated mice when
compared to control mice, suggesting a decrease in the stiffness of the cervix in the mice that deliver
preterm. D: Collagen staining. The collagen was determined by Masson's trichrome staining (upper
panels) and by IHC using a specific antibody that reacts with mouse collagen type I (lower panels).
Dense network of collagen fibers was observed in control cervix (left panels). Disperse thin fibers of
collagen were observed in the cervix of LPS- (middle panels) and RU486-treated mice (right panels).
E:In situ zymography using DQ gelatin (upper panel), DQ collagen type I (middle panel), and DQ
collagen type IV (lower panel). Increased fluorescence (increased gelatin and collagen I and IV
degradation) is present in the cervix of LPS- (middle panel) and RU486-treated mice (right panels).
Weak fluorescence (low gelatin and collagen degradation) is observed in control cervical tissue (left
panels). F: Detection of matrix metalloproteinase (MMP)-2 and MMP-9 in cervical tissues by IHC.
Increased MMP-9 staining was observed in the cervix of LPS- (middle upper panel) and RU486-treated
mice (right upper panel) when compared to control mice (left upper panel). On the other hand no
increase in staining for MMP-2 was observed in the cervix of LPS- (middle lower panel) and RU486treated mice (right lower panel). The weak staining for MMP-2 in these mice was comparable to control
mice (left lower panel).
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to control mice, suggesting a decrease in the stiffness of the cervix in mice that deliver
preterm (Figure 1C). Masson's trichrome (TC) staining revealed a decreased number of
collagen fibers in the cervix of mice treated with LPS or RU486 antepartum (Figure 1D,
middle and right upper panels) when compared to the high density of collagen fibers
observed in control mice (Figure 1D, left upper panel). Immunohistochemical studies
with specific antibodies against mouse collagen I showed a similar distribution pattern to
the TC staining (Figure 1D, lower panels).

Collagen packing was disorganized,

collagen fibers looked thinner, and greater spacing between fibers were observed in
LPS- and RU486-treated mice (Figure 1D, middle and right lower panels) when
compared to age-matched controls (Figure 1D, left lower panel).
Decreased density in collagen fibers was associated with increased cervical
MMP activity (Figure 1E). In situ zymography using DQ gelatin and DQ collagen I and
IV as substrate revealed an increase in activity of MMPs with gelatinolytic and
collagenolytic activity in the cervix of mice treated with LPS or RU486 (Figure 1E).
Collagen is degraded by the sequential action of many MMPs to gelatin, and
subsequently gelatin is degraded by MMPs. Both MMP-9 and MMP-2 have the capacity
to cleave collagen I, collagen IV, and gelatin.39

Robust MMP activity (green

fluorescence) was observed in the cervix of LPS- and RU486-treated mice incubated
with DQ gelatin and DQ collagen I and IV (Figure 1E) in contrast with the weak
fluorescence (diminished MMP activity) observed in the cervix of control mice (Figure
1E, left panels). Taken together, these data suggest that MMP-9 and/or MMP-2 might
be responsible for the degradation of the cervical matrix during the antepartum period,
decreasing cervical tensile strength, and leading to PTD in LPS- and RU486-treated
mice.
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Immunohistochemical studies identified MMP-9 as the main collagenase involved
in cervical remodeling in LPS- and RU486-treated mice that deliver preterm. Increased
MMP-9 staining (Figure 1F, middle and right upper panels), but not MMP-2 (Figure 1F,
middle and right lower panels) was observed in the stroma and epithelium of mice with
inflammation-induced preterm birth compared to age-matched controls (Figure 1F,
upper and lower right panels).
Complement Activation in LPS- and RU486-Treated Mice
Knowing that complement activation plays a crucial role in many pregnancy
complications, we investigated if complement activation is a mediator in the
pathogenesis of the cervical changes that lead to PTD in LPS- and RU486-treated mice.
In accordance with our hypothesis, increased C3 deposition was observed in the
cervical columnar epithelium in LPS- and RU486-treated mice (Figure 2A) when
compared to gestational age-matched controls (Figure 2A).

In addition, increased

C3adesArg levels were measured in serum of LPS- and RU486-treated mice during
antepartum compared to control mice (Figure 2B).

Complement split product

C5adesArg was also increased in LPS- and RU486-treated mice when compared to
controls (Figure 2C).
Inflammatory Cells in the Cervical Tissue
It has been suggested that inflammatory cells play an important role in the cervical
changes before delivery at term. Thus, we investigated if inflammatory cells are present
during cervical remodeling in preterm delivery induced by LPS and RU486.
Immunohistochemical

studies

with

anti-F480

antibodies

showed

increased

macrophages infiltration in the cervical stroma, epithelium, and mucus in LPS- and
RU486-treated mice compared to gestational age-matched controls (Figure 2D). The
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presence of macrophages in the cervix of mice that deliver preterm suggests that
macrophages may be involved in the cervical changes that precede PTD.

Figure 2. Complement activation and macrophages/monocytes infiltration in the cervix of LPSand RU486-treated mice. A: Immunohistochemical determination of C3 in cervical tissue. Arrows
indicate C3 deposition (brown staining) in the columnar epithelium (CE) in LPS- (middle panel) and
RU486-treated mice (right panel). No complement deposition was observed in the cervical tissue of the
control mice (left panel). Original magnification is ×20. B: Serum C3adesArglevels in control, LPS-, and
RU486-treated mice. Statistically different from control, *P < 0.05 (n = 5 to 6 mice/group). C: Serum
C5adesArglevels in control, LPS-, and RU486-treated mice. Statistically different from control, *P < 0.05
(n = 5–6 mice/group). D: F4/80 staining in cervical tissue. Increased macrophage infiltration (brown color)
was observed in the cervical stroma, epithelium, and mucus of LPS- (middle panel) and RU486-treated
mice (right panel). Few macrophages were observed in the cervix of age-matched control mice (left
panel). Original magnification is ×20. The inserts in the middle and right panels include macrophages
shown at a higher magnification. E: Gr-1 staining in cervical tissue. Few Gr-1+ neutrophils cells were
found in the cervical stroma of control (left panel), LPS- (middle panel), and RU486-treated mice (right
panel). Original magnification is ×20. F: Delivery time in control, LPS-, and LPS plus anti-F4/80 (n = 4–6
mice/group). Significantly different from control, *P < 0.05. G: Trichrome (TC) staining for collagen I and
for matrix metalloproteinase (MMP)-9 in cervical tissue of LPS-treated mice depleted of macrophages
with anti-F4/80. Abundant collagen fibers were shown with TC staining (left panel) and by IHC with
antibodies against collagen I (middle panel). Staining for MMP-9 was negative in F480 plus LPS-treated
mice (right panel). H:In situ zymography using DQ-gelatin and DQ-collagen I as substrate in LPS-treated
mice pretreated with anti-F4/80. Gelatin and collagen I degradation was not observed in cervical tissue
from F4/80 plus LPS-treated mice. Original magnification is ×20.
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Few positive Gr-1 cells were observed in the cervix of control, LPS- and RU486treated mice (Figure 2E) suggesting that neutrophils might not be involved in the
cervical remodeling that precedes PTD in LPS- and RU486-treated mice.
Macrophages Depletion Prevents PTD in LPS-Treated Mice
To examine the relative importance of macrophages in LPS-induced cervical
changes and preterm delivery, we depleted macrophages by treating mice with antiF4/80 antibodies. In the absence of macrophages, treatment with LPS did not cause
preterm birth (Figure 2F) nor were there inflammatory infiltrates in the cervix (data not
shown).

Furthermore, without macrophages infiltration there was less collagen

degradation, as shown in Figure 2G in which TC staining and IHC with anti-collagen I
antibodies showed a dense network of collagen fibers comparable to control mice
(Figure 1D). Decreased MMP-9 activity (Figure 2G) and decreased proteolytic activity
against gelatin and collagen I (Figure 2H) was also observed in LPS-treated mice
depleted of macrophages.

Diminished collagen degradation and MMP-9 activity

suggest that macrophages may play a role in cervical remodeling that leads to PTD in
LPS-treated mice. LPS-treated mice that received isotype control antibody delivered
within 24 to 36 hours (data not shown).
C5a and C5aR Interaction Is a Critical Mediator of LPS- and RU486-Induced Preterm
Delivery
Because receptors for anaphylotoxin C5a (C5aR) are widely expressed in
inflammatory cells and endothelial cells among others,40,41 we hypothesized that C5a
and C5aR interactions mediate cervical remodeling and PTD in LPS- and RU486treated mice. To test this hypothesis we performed studies in C5aR−/− mice. Untreated
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Figure 3. C5aR deficiency and progesterone prevents preterm labor/delivery (PTD). A: Delivery time
in control and LPS- or RU486-treated, wild-type, C5aR+/+ and C5aR−/− mice (n = 5 to 7 mice/group).
Significantly different from control, *P < 0.05. B:In situ zymography using DQ gelatin (left panels), DQ
collagen I (middle panels), and DQ collagen IV (right panels). In contrast to the increased fluorescence
(increased gelatin and collagen degradation) observed in the cervix of LPS- (Figure 1E, middle panels)
and RU486-, wild-type treated mice (Figure 1E, right panels), gelatin and collagen degradation was not
observed in LPS- (upper panels) and RU486-treated, C5aR−/− mice (lower panels) comparable to
control cervical tissue (Figure 1E, left panels). C: Gel zymography of nonreduced cervical tissue lysates.
Purified matrix metalloproteinase (MMP)-9 was used as a control. Increased MMP-9 was observed in
wild-type (WT) mice treated with LPS. D: Immunohistochemical detection of MMP-9 revealed weak
staining for MMP-9 in LPS- (left panel) and RU486-treated, C5aR−/− mice (right panel). E: Collagen
detection by trichrome staining and IHC. Dense network of collagen fibers was observed in the cervix of
LPS- (upper panels) and RU486-treated (lower panels) C5aR−/− mice in contrast with the disperse thin
fibers of collagen observed in the cervix of LPS- and RU486-treated, wild-type, C5aR+/+ mice (Figure 1D,
middle and right panels, respectively). F: Biomechanical studies of the cervix. The elastic modulus
(measure of the tissue stiffness) was decreased in the cervical tissue of LPS- and RU486-, wild-type
treated mice when compared to control mice. Decreased elastic module was not observed in LPS- and
RU486-treated C5aR−/− mice, indicating an increase in the stiffness of the cervix in these mice. Elastic
module values in LPS- and RU486-treated mice were comparable to age-matched control mice (n = 4
mice/group). Significantly different from control mice (Ctrl), *P < 0.05. G: Complement activation triggers
release of pro-MMP-9 by murine macrophages in vitro. Splenic macrophages were stimulated with C5a
and C5a plus progesterone (P). Culture supernatants were collected after 12 and 24 hours and analyzed
for MMP-9 by enzyme-linked immunosorbent assay (n = 4 experiments/group; *P < 0.05 versus untreated
cells).
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C5aR−/− (control) mice have normal pregnancies and give birth at day 20 to day 21,
similar to C5aR+/+, wild-type mice (Figure 3A). In wild-type, C5aR+/+ mice, LPS, and
RU48-induced PTD (Figure 3A). Neither LPS nor RU486 treatment induced PTD in
C5aR−/− mice (Figure 3A).

Increased MMP activity observed in LPS- and RU486-

treated, wild-type, C5aR+/+ mice (Figure 1E) was not observed in C5aR−/− mice
(Figure 3B). Gelatin zymography confirmed these results (Figure 3C). A diminution in
MMP-9 activity was observed in the cervix of LPS-treated, C5aR−/− mice (Figure 3C,
lane 4) when compared to wild-type, C5aR+/+ mice (Figure 3C, lane 3). Staining for
MMP-9 was negative in cervical tissue from LPS- (Figure 3D, left panel) and RU486treated mice (Figure 3D, right panel). As expected, the absence of MMP9 expression
and activity in LPS- or RU486-treated, C5aR−/− mice (Figure 3, B and D) was
correlated with diminished collagen degradation.

Abundant collagen fibers were

observed in the cervix of LPS- (Figure 3E, upper panels) and RU486-treated, C5aR−/−
mice (Figure 3E, lower panels).

The histological studies correlated with the

biomechanical studies of the cervix. Decreased distensibility (increased elastic module)
values were observed in the cervix of C5aR−/− mice treated with LPS or RU486 when
compared to wild-type mice (Figure 3F). These data suggest that C5aR is required for
preterm cervical remodeling and PTD in LPS- and RU486-treated in mice.
Progesterone Prevents Cervical Remodeling and PTD in LPS-Treated Mice
As progesterone withdrawal has been related with PTD, we measured
progesterone levels in LPS-treated mice. We found that serum progesterone levels in
LPS-treated mice antepartum were not different from age-matched control mice (42 ± 7
ng/mL in LPS-treated mice (n = 6) versus 39 ± 6 ng/mL in control mice (n = 7).
Because some studies reported that progesterone and 17 OH hydroprogesterone
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Figure 4. Progesterone
(P) prevents preterm
labor/delivery (PTD) in
mice. A: Delivery time in
control, LPS, and LPS
plus P-treated mice (n =
5 to 7 mice/group).
Significantly
different
from control, *P < 0.05.
Note that progesterone
prevents PTD in LPStreated
mice.
B:
Histological studies. In
situ zymography using
DQ gelatin, DQ collagen
I, and DQ collagen IV in
the cervix of LPS plus Ptreated mice. Decreased
degradation of gelatin
and
collagen
was
observed in LPS plus Ptreated
mice
when
compared
to
LPStreated mice (Figure 1E,
middle
panels).
C:
Staining for collagen in
cervical tissue from LPS
plus
P-treated
mice
showed
increased
density of collagen fibers
(left and middle panels)
when compared to LPStreated mice (Figure 1D,
middle
panels).
Increased staining for
MMP-9 observed in the
cervix of LPS-treated
mice (Figure 1F, upper
middle panel) was not
observed when mice
were supplemented with
progesterone
(right
panel). D: Negative staining for F4/80 in LPS plus P-treated mice. E: Biomechanical studies of the cervix.
The elastic modulus (measure of the tissue stiffness) was decreased in the cervical tissue of LPS-treated
mice when compared to control mice. Decreased elastic module was not observed in LPS-treated mice
treated with P, indicating an increase in the stiffness of the cervical tissue in these mice. Elastic module
values in LPS plus P-treated mice were comparable to age-matched control untreated mice (n = 3 to 4
mice/group). Significantly different from control mice (Ctrl), *P < 0.05. F: Immunocytochemical detection
of C5aR on murine cultured macrophages incubated without P and increasing doses of progesterone: 10
mmol/L, 20 mmol/L, and 40 mmol/L. G: Computerized quantification of C5aR staining on macrophages.
Decreased staining for C5aR was observed in macrophages incubated with increasing doses of
progesterone (white bars). Increased staining was observed in permeabilized cells (black bars)
suggesting that C5aR is localized intracellularly in macrophages incubated with progesterone.
Significantly different from control, *P < 0.05.
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caproate can reduce the rate of PTD in patients22-31 and because progesterone inhibits
the release of MMP-9 from macrophages in our mouse model, we investigated if
progesterone prevented PTD in LPS-treated mice.

Pretreatment with progesterone

completely reduced the incidence of inflammation-induced PTD in LPS-treated mice
(Figure 4A). Mice treated with progesterone and LPS delivered at a time not different
from control untreated mice (Figure 4A). The cervical changes induced by LPS were
not observed in mice pretreated with progesterone. Neither increased MMP activity
(Figure 4B) nor increased collagen degradation (Figure 4C) was observed in LPStreated mice pretreated with progesterone. In addition, progesterone prevented MMP-9
increase in cervical tissue in LPS-treated mice (Figure 4C). Interestingly, diminished
macrophages infiltration was observed in the cervix of LPS plus progesterone-treated
mice

(Figure

4D),

suggesting

an

anti-inflammatory

effect

of

progesterone.

Biomechanical studies performed in cervical tissue from LPS plus progesterone-treated
mice showed increased elastic module values (increased stiffness) when compared to
mice treated only with LPS (Figure 4E), suggesting that progesterone prevents
inflammation-induced cervical remodeling in LPS-treated mice.
Progesterone Diminishes the Expression of C5aR in the Surface of Macrophages
Progesterone prevented inflammation-induced cervical remodeling and PTD in
LPS-treated mice. Thus, progesterone would need to have anti-inflammatory effects to
be able to effectively reduce the incidence of PTD. We hypothesized that the antiinflammatory effect of progesterone observed in our studies is due to the downregulation of C5aR on macrophages. Decreased staining for C5aR was observed in
macrophages incubated with progesterone (Figure 4F).

The amount of C5aR

expressed on the surface of macrophages diminished with increasing doses of
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progesterone (Figure 4F). Decreased expression of C5aR was not associated with
decreased synthesis of C5aR. RT-PCR studies showed comparable levels of C5aR
message in macrophages incubated with or without progesterone (false discovery rate <
0.1, fold change > 1.5). When macrophages were permeabilized before staining for
C5aR, positive staining for C5aR in the cytoplasm was observed (Figure 4G).

A

positive correlation was observed between cytoplasmic staining for C5aR and
increasing doses of progesterone (Figure 4G). This data suggests that progesterone
induces the internalization of C5aR and thus diminishes the release of MMP-9,
preventing cervical remodeling and PTD.
Discussion
We have shown by using two mouse models of preterm delivery induced by
inflammation that complement activation plays an essential and causative role in the
cervical structural changes that leads to preterm parturition. These studies identified
complement split product C5a and macrophages as crucial mediators in the preterm
birth.
In both mouse models of PTD, increased macrophages infiltration was observed
in the cervical tissue, confirming the role of inflammation in PTD induced by LPS or
RU486.

The PTD model induced by RU486 was originally described as a model

induced by progesterone withdrawal,36 but it is now known that recruitment of immune
cells that remodel the cervix is a crucial feature in the mechanism responsible for
preterm birth in this model.9,10 Our results showing increased cervical macrophages
infiltration and increased C3a and C5a plasma levels clearly indicate that inflammation
occurs in RU486 and LPS–treated mice that deliver preterm.
Collagen is the main component of the cervical stroma. These proteins are rigid
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and nonextensible, and thus are responsible for the mechanical properties of the cervix.
Throughout pregnancy collagenases slowly remodel (so–called softening and ripening)
the collagen matrix in preparation for labor and delivery.

In both models of PTD,

extensive collagen degradation and decreased cervical stiffness occur, suggesting that
these cervical changes are responsible for early delivery induced by inflammation.
Using histochemical and zymography techniques, we identified MMP–9 as a
crucial metalloproteinase involved in the premature cervical remodeling observed in
LPS– and RU486–treated mice.

MMP–9 not only degrades gelatin, it is also a

collagenase with the capacity to cleave collagen I, III, and IV.39 Degradation of collagen
fibers and disorganized collagen packing with greater spacing between fibers was
observed in the cervix in LPS- and RU486-treated mice antepartum.

By digesting

collagen and gelatin, MMP-9 weakens the collagen matrix and thus the cervix dilates
and PTD occurs.
We hypothesized that inflammation caused by LPS or RU486 creates
pathological changes that accelerate the normal progress of events that lead to delivery.
Thus, we investigated if inflammatory cells play a role in the cervical changes that lead
to PTD induced in LPS- or RU486-treated mice. We found increased macrophages, but
not neutrophils, infiltrating the cervical tissue in mice that deliver preterm. Depletion of
macrophages abrogated cervical ripening and rescued pregnancies to term in LPStreated mice, confirming the crucial role of macrophages in this model of PTD.
Complement activation has been related with many inflammation-mediated
pregnancy disorders in mice and humans.12,43-46 Increased C3a and C5a plasma levels
were observed in the antepartum in mice treated with LPS or RU486 that deliver
preterm. C5a is a potent chemotactic factor and activator of macrophages. Indeed, we
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found that macrophages release MMP-9 in response to C5a and thus are an important
source of MMPs.
In vivo studies confirmed the role of C5a and C5aR in the premature cervical
remodeling and delivery in LPS- or RU486-treated mice.

LPS- or RU486-treated,

C5aR−/− mice showed collagen fibers densely packed and low metalloproteinase
activity in the cervix. All these features are consistent with nondistensible cervixes and
pregnancies that will go to term. Indeed, PTD was not observed in LPS- or RU4786treated C5aR−/− mice. We also need to consider the possible contribution of cervical
fibroblasts to the release of MMPs and the onset of PTD.47 The absence of C5aR
mRNA described in human cervical cancer TC-1 cells,48 suggests that cervical cells do
not express C5aR. However, cervical fibroblasts can also amplify MMPs release by a
complement independent pathway.
Collectively our study demonstrates that LPS ascends from the vagina to the
cervix, where the complement cascade is activated. C3b is deposited on the cervical
Figure 5. Proposed mechanism
for
LPS-induced
cervical
remodeling and preterm birth.
LPS ascends from the vagina to
the cervix, where the complement
cascade is activated. C3b is
deposited
on
the
cervical
epithelium and complement split
product C5a is generated. C5a
attracts
and
activated
macrophages to the cervical
stroma. In response to C5a
macrophages
release
matrix
metalloproteinase (MMP)-9 that
digests collagen leading to cervical
remodeling, increased cervical
distensibility, and preterm birth.

epithelium and complement split product C5a is generated. C5a attracts and activated
macrophages to the cervical stroma. In response to C5a, macrophages release MMP-9
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that digests collagen leading to cervical remodeling and preterm birth (Figure 5).
Based on the beneficial effects of progesterone in some human studies22-31 and
on the anti-inflammatory effects of progesterone,33,49 we investigated if progesterone
supplementation could prevent cervical remodeling and preterm birth in mice treated
with LPS.

Our studies demonstrated that progesterone pretreatment abrogated the

cervical changes that lead to PTD in LPS-treated mice.

Neither increased MMPs

activity nor collagen degradation and loss of tensile strength was observed in the
cervixes of LPS-treated mice that received progesterone. In addition, progesterone
inhibited C5a-induced release of MMP-9 from macrophages in vitro. C5aR expression
was reduced on the surface of macrophages incubated with progesterone in
comparison to those incubated with only media suggesting that decreased C5aR might
contribute to the inhibitory effect of progesterone on MMPs release. However, when
macrophages incubated with progesterone were permeabilized before staining, C5aR
was clearly detectable in the cytoplasm of macrophages. This data suggests that C5aR
is internalized in macrophages incubated with progesterone. Internalization of C5aR
(as many other G-coupled receptors) has been described in neutrophils and
macrophages in mice and may account for diminished activity observed in these
cells.50,51

Internalization of C5aR by progesterone can also explain the diminished

macrophage infiltration observed in LPS plus P-treated mice. This observation is
supported by the findings of Timmons and Mahendroo.10
The protective effects of progesterone in PTD can also be caused by the
inhibitory effects of progesterone on MMP-9 synthesis.

It has been reported that

progesterone inhibits MMP-9 synthesis in rabbit uterine cervix42 and ischemic brains in
rats.52 However, we did not find decreased MMP-9 mRNA in macrophages incubated
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with progesterone, but we found decreased release of MMP-9. Internalization of C5aR
on macrophages and consequent diminished cell activation by C5a may explain the
diminished release of MMP-9 from macrophages incubated with progesterone. The fact
that progesterone prevents premature birth in the mouse model of LPS-induced PTD
that showed no diminution in serum progesterone levels suggests that progesterone is
acting as an anti-inflammatory molecule.

Moreover, progesterone diminished

macrophages infiltration in cervical tissue in LPS-treated mice. Several studies support
the concept that progesterone has anti-inflammatory properties.49,53

Progesterone

suppresses estrogen-induced C3 expression in the mouse oviducts and uterus.54
Another report showed that progesterone suppresses the complement-mediated attack
to allogenic chick embryos.55 Thus, we also need to consider that progesterone may
prevent PTD in LPS-induced PTD by modulating the expression and/or activation of
complement components.
Our studies showed the effectiveness of progesterone in preventing LPS-induced
cervical remodeling. However, we also need to consider that progesterone may also
contribute to the prevention of PTD by promoting uterine quiescence. Several studies
demonstrated that progesterone promotes myometrial relaxation.56-58
Our finding that the absence of C5aR prevents PTD in the mouse models may
have important therapeutic implications. Blocking the complement cascade at C5a and
CaR interaction inhibits mediators and effectors of cervical remodeling and prevents
PTD, suggesting that complement might be a good target for therapy in women with
PTD.

One of the few current treatments for women at risk of preterm labor is

progesterone, which can diminish the expression of C5aR on the surface of
macrophages and thus prevent inflammation, the release of MMPs, and cervical
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remodeling, reinforcing the idea that the complement system is a promising target for
therapy in this serious pregnancy complication. Complement inhibitors are now being
tested in patients with inflammatory, ischemic, and autoimmune diseases. Identifying
complement-related markers that predict high risk for PTD will allow us design
interventions that prevent or arrest this pathological process, which compromises the
survival of the neonates born prematurely.
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CHAPTER 2
COMPARISON OF THE MECHANISMS RESPONSIBLE FOR CERVICAL
REMODELING IN PRETERM AND TERM LABOR
Introduction
The process of parturition has been extensively studied.

However, the

mechanisms responsible for the onset and progression of labor are multifactorial and
not completely understood.1,59,60 Understanding the mediators and effectors of labor
could have enormous benefit, allowing potential interventions for efficient induction of
labor or conversely in postponing unwanted labor. Identification of targets to regulate or
terminate labor is of particular importance in the treatment and prevention of preterm
labor, which continues to be a major public health issue and the number one cause of
neonatal death.

Among the important events contributing to labor is the ripening/

remodeling of the cervix.2,38,61 Changes in the cervical structure soften and dilate the
cervix allowing the passage of the fetus forced by rhythmic myometrial contractions.
Chapter 1 reveals how we demonstrated that complement activation plays a crucial role
in the cervical remodeling process that leads to preterm labor. Using a mouse model of
PTD induced by LPS we found that complement split product C5a attracts and activates
macrophages to the cervix. In response C5a, macrophages release metalloproteinases
(MMPs) that degrade collagen, increasing the cervix distensibility and leading to PTD in
mice.62
The aim of this study is to characterize the term cervical ripening process and
compare it with preterm. Knowing that complement activation plays a causative role in
PTD in mice, we decided to study if complement activation also plays a role in cervical
remodeling at term.

If complement activation is not involved in the physiological
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process that leads to term delivery we will then have identified a possible specific and
selective target to prevent PTD and thus improve neonatal health.
Materials and Methods
Ethics Statement
As noted in chapter 1, our animal studies were performed following the Russell
and Burch Three R's (Replacement, Reduction and Refinement) concept to minimize
animal use and pain or distress while still achieving the critical scientific objectives. All
the experiments performed were conducted in accordance with the National Institute of
Health guidelines on laboratory animals and with approval from the Wayne State
University (protocol A 09-08-09) and York College CUNY committee on Animal Use and
Care (protocol R-3-2009).
Animals
C57BL/6 timed-pregnant mice were purchased from Jackson Laboratories (Bar
Harbor, ME).

Animals were shipped on day 10 to 12 after mating.

Animals were

acclimated in the animal facility for 3 to 5 days before use in these experiments.
Cervical remodeling was studied in mice at term and during preterm labor. A
mouse model of PTD which resembles most clinical scenarios in that localized
inflammation occurs without systemic maternal illness was used. In this model, mice
were treated with LPS (E. coli serotype 055:B5 (250 µg/mouse, intravaginally)) on day
15 of pregnancy. Most of the pregnant females (94.7%) delivered within 24–36 hours of
LPS administration.62 No maternal morbidity or mortality was observed in this model.
Pregnant mice treated with LPS were euthanized antepartum (between 12–18
hours after treatment) or during delivery (intrapartum). Delivery was considered preterm
if it occurred within 48 hours after LPS administration (before gestational day 17). In our
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animal facilities, term delivery occurs between day 20 and day 21 of pregnancy. Control
mice were euthanized antepartum (day 17, 18 and 19) or intrapartum (by direct
observation after the passage of 1 or 2 pups). Blood samples and cervical tissue were
collected.
Serum complement activation products and progesterone levels
To determine the role of complement activation in term and PTD, generation of
complement split products C3a and C5a were measured by measuring the more stable
metabolites C3adesArg and C5adesArg in serum.

C3a(desArg) and C5a(desARg)

result from the removal of the C-terminal arginine by ubiquitous carboxypeptidases and
have longer half time than C3a and C5a.

C3adesArg in serum was measured by

sandwich ELISA as previously described in Chapter 1 using rat anti-mouse C3a and
biotin rat anti-mouse C3a.

Both antibodies were purchased from BD Biosciences

Pharmingen, CA. A Standard curve was performed using purified mouse C3a protein
(native) (BD Biosciences Pharmingen). C5adesArg was also measured by sandwich
ELISA using rat anti-mouse C5a and biotin rat anti-mouse C5a. Both antibodies and
mouse purified C5a protein for the standard curve were purchased from BD
Biosciences.
Progesterone levels were measured by competitive enzyme immune assay
(Cayman Chemicals, Ann Arbor, MI).
Immunohistochemistry and immunocytochemistry
Cervical tissues isolated during antepartum and intrapartum were frozen in
O.C.T. compound, and cut into 10 µm sections. Sections were stained for C3 with
rabbit anti-mouse C3 (LifeSpan Biosciences, Seattle, WA), neutrophils were stained
with rat anti-mouse granulocyte RB6-8C5 mAb (BD Biosciences Pharmingen) and

30
macrophages with F4/80 (Novus Biologicals, Inc, Littleton,CO). MMP-2 and MMP-9
were detected in frozen cervical sections using rabbit polyclonal anti-mouse MMP-2 and
MMP-9 antibodies (Abcam, Cambridge, MA). Collagen I distribution was determined
using Masson's Trichrome staining and by immunohistochemistry using a polyclonal
antibody against collagen type I (ACRIS Antibodies, GmbH, Herford, Germany). HRPlabeled specific secondary antibodies and DAB as substrate were used to develop the
respective reactions.
In situ zymography
Metalloproteinases MMP-2 and MMP-9 activity against collagen I and IV and
gelatin were measured by in situ zymography as previously described in chapter 1.37
Briefly, 10-µm-cervix sections were washed in PBS and then incubated for 4 hours with
different MMPs DQ substrates.

DQ-gelatin, DQ-collagen I and DQ collagen IV

(Invitrogen, Carlsbad, CA). The enzyme-driven hydrolysis of these substrates results in
an increase in fluorescence signal. Increased fluorescence indicates increased gelatin
and collagen degradation by MMPs. In parallel, control sections were preincubated with
buffer containing the MMP inhibitor EDTA to indicate the contribution of MMPs. The
reaction was stopped by a 10 minutes incubation in 4% paraformaldehyde-PBS.
Finally, mounting medium supplemented with DAPI (Vector Laboratories, Burlingame,
CA) was applied.

Sections (4–6 tissue sections/group) were observed under a

fluorescence microscope Nikon Eclipse 50i (Nikon Inc, Melville, NY) and photographs
were taken using a Nikon DigiSight Color Digital Camera System and NIS-Elements
Research Imaging Software.
Human cervical epithelial cells
A cell line from normal human endocervical epithelia immortalized by expression
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of human papillomavirus (Endl/E6E7) (ATCC Manssas, VA) was used in in vitro
studies.63 The morphology of these immortalized cells corresponds to glandular tall
columnar epithelial cervical cells and closely resembles that of the tissue of origin and
primary cultures. Thus, End1/E6E7 cells constitute a reproducible in vitro model to
study the role of these epithelial cells in cervical ripening. End1 cells were cultured as
previously described.63

The expression of C5aR on End-1cells was studied by

immunohistochemistry using anti-human C5aR antibodies (Cell Sciences, Canton, MA).
MMP-2, MMP-9 and progesterone receptors (PR) expression in End-1 cells was also
evaluated by RTPCR. Aliquots of End1 cells were incubated for 16 h with progesterone
(1 mg/ml) and synthesis of MMP-2 and MMP-9 was studied by RT-PCR.
Aliquots of End1/EGE7 cells were cultured on cell chamber slides incubated with
and without progesterone (1 mg/ml) for 16 h and then subjected to in situ zymography
using DQ-gelatin and DQ-collagen I as previously described. Immunohistochemistry
was performed to detect MMP-2 and MMP-9 using rabbit polyclonal anti-mouse MMP-2
and MMP-9 antibodies (Abcam, Cambridge, MA) followed by a FITC-labelled anti-rabbit
antibody (Abcam, Cambridge, MA).
Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR)
To determine whether End1 synthesize MMP-2, MMP-9 and PR, qRT-PCR was
performed. RNA was harvested from End1 cells with RNeasy Mini Kit (Qiagen,
Valencia, CA) and 1 µg of total RNA was reverse transcribed. Primer sequences mouse
GAPDH, human MMP-2, MMP-9 and PR were obtained from Applied Byosystems
(Foster City, CA). Relative expression was normalized for levels of GAPDH. Relative
quantification of MMP-2 and MMP-9 between End-1 cells incubated with and without
progesterone gene expression was performed using 2−DDCT data analysis.

The

32
comparison was performed in pairs using the same target gene and the same End-1
samples. CT = Threshold value; DCT = average target CT – average GAPDH CT; DDCT
(for the same target gene) = average DCT End-1 incubated with progesterone- average
DCT End-1 incubated without progesterone. DDCT = 0 when the End-1 of interest are
used as calibrator. 2−DDCT = normalized target gene amount (MMP-2 or MMP-9) relative
to target gene amount in End-1 cells incubated without progesterone. * p<0.05, n = 4.
Results
Serum progesterone levels in term and preterm delivery
In most mammalian species aside from the great apes, labor is initiated by a
decrease in circulating progesterone levels (progesterone withdrawal).64 Indeed, we
found that in mice, serum progesterone levels drop dramatically intrapartum when
compared to antepartum levels (Figure 6). On the other hand, mice treated with LPS
that deliver preterm do not show a diminution in progesterone levels compared to
antepartum levels. Progesterone levels in antepartum were comparable to intrapartum
values in LPS-treated mice (Figure 6), suggesting that progesterone withdrawal is not
involved in preterm parturition in LPS-treated mice.
Figure 6. Serum progesterone
levels in PTD and term delivery.
Antepartum LPS serum samples
were collected at day 15 of
pregnancy, intrapartum LPS samples
at days 16 and 17, antepartum term
samples at days 17, 18 and 19 and
intrapartum term at days 20 and 21.
Note that progesterone levels drop
dramatically near parturition time
(days 20 and 21) in control mice at
term while LPS-treated mice that
delivered preterm did not show
changes in progesterone levels. *
Different from antepartum, P<0.05. 3
to 5 samples were analyzed at each
time point.
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Complement activation in term and preterm delivery
Complement activation involves the cleavage of C3 into C3b that deposits on the
tissue, and C3a that can be measured in systemic circulation. Increased C3 deposition
was observed in the cervix of LPS-treated mice with antepartum and intrapartum
(Figure 7 A). Prompted by the findings that complement activation triggers cervical
remodeling and preterm labor (Figure 7A), we investigated if complement activation also

Figure 7. Complement activation in PTD and term delivery. A- Complement C3 deposition in the
cervix of mice that delivered preterm antepartum and intrapartum. Black arrows point to complement
deposition in the cervical columnar l epithelium (CE). Original magnification is ×20. B- Complement C3
deposition in the cervix of mice that deliver at term. C3 deposition was not observed antepratum (days 17,
18 and 19) or intrapartum. Original magnification is ×20. For C3 determination, 4 slides per animal were
stained and 6–8 animals were studied in each group. C–D C3adesArg and C5adesArg levels in serum
from mice with PTD and term delivery collected antepartum and intrapartum. Antepartum LPS serum
samples were collected at day 15 of pregnancy, intrapartum LPS samples at days 16 and 17, antepartum
term samples at days 17, 18 and 19 and intrapartum term at days 20 and 21. * Statistically different from
control, p<0.05. n = 5–6 mice/group.
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contributes to term labor. Surprisingly, no C3 cervical deposition was observed in mice
that delivered at term (Figure 7B). Negative staining for C3b was observed in cervical
samples collected antepartum (days 17, 18 and 19) or intrapartum (Figure 7B). In
addition, mice that delivered at term showed no increase in serum C3a and C5a levels,
neither antepartum nor intrapartum (Figure 7C and 7D). C3a and C5a levels in mice
that delivered at term were significantly lower than those observed in mice that
delivered preterm (Figure 7C and 7D). The absence of complement split products at
term labor suggests that complement activation is not involved in the physiological
process that leads to term parturition.
Inflammatory cells in term and preterm delivery
In Chapter 1 we previously demonstrated that inflammation plays a crucial role
the cervical remodeling that leads to PTD. To determine whether inflammatory cells are
also required for the cervical ripening at term, we performed immunohistochemical
studies in cervical samples harvested antepartum and intrapartum in control untreated
mice. The presence of macrophages was studied using antibodies against F4/80 and
neutrophils were identified with antibodies anti-Gr1.

Increased macrophages were

observed antepartum and intrapartum in the cervix of mice that deliver preterm (Figure
8). In contrast, no macrophages were observed in samples collected antepartum and
intrapartum at term (Figure 8).
The absence of inflammatory cells indicates that the cervical remodeling that
leads to term labor is not dependent on leukocytes. That inflammatory cells do not
participate in the cervical changes that contribute to term labor constitute a significant
difference between the term and preterm mechanisms of labor.
Staining with anti-Gr1 showed that neutrophils are not present either in the cervix
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of mice at term or preterm (Figure 8).

Figure 8. Inflammatory cells in cervical tissue from mice that deliver preterm and at term. F4/80
staining in cervical tissue. Increased macrophage infiltration (black arrows) was observed in the cervix of
mice that deliver preterm antepartum and intrapartum. In contrast no macrophages were observed in the
cervix of mice that deliver at term antepartum and intrapartum. Original magnification is ×20. B- Gr-1
staining in cervical tissue. No neutrophil infiltration was observed at preterm or term cervical samples.
Original magnification is ×20. 4 slides per animal were stained and 6–8 animals were studied in each
group.

MMPs synthesis in human cervical columnar epithelial cells End1
MMPs participate in cervical remodeling by degrading the network of collagen
fibers and thus increase the distensibility required for delivery.3,65

It has been

extensively documented that inflammatory cells, macrophages and neutrophils, are a
good source of MMPs. The absence of inflammatory cells in the cervical tissue at term
leads as to investigate other possible sources of MMPs. In the absence of inflammatory
cells, cervical columnar epithelial and stromal fibroblastic cells could be alternative
sources of MMPs. To determine whether cervical columnar epithelial cells are capable
of synthesizing MMPs, we performed qRT-PCR. MMP-2 and MMP-9 mRNA was found
in End-1 cells (Figure 9B), indicating that cervical columnar epithelial cells can be a
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source of MMPs in cervical remodeling at term. In situ zymography studies show that
End-1 cells produce and release proteases that digest gelatin and collagen I (Figure
9C).

These active proteases were identified as MMP-2 and MMP-9 by

immunohistochemistry (Figure 9C).

Figure 9. Cervical MMPs activity and collagen degradation at PTD and term delivery. AImmunohistochemical determination of C5aR in End-1 cervical columnar epithelial cells. n = 4. B–
Relative quantification of MMP-2 and MMP-9 between End-1 cells incubated with and without
progesterone. * p<0.05, n = 4 mice/group. Note that in End-1 cells incubated with progesterone a ~50%
reduction in MMP-2 and MMP-9 mRNA was observed when compared to untreated cells. C- In situ
zymography using substrates DQ-gelatin and DQ-collagen I and immunohistochemical detection of MMP2 and MM9-9 en End-1 cells incubated with and without progesterone. The green fluorescence indicate
the substrate has been digested. MMP-2 and MMP-9 were detected by IHC using specific antibodies
followed by FITC-labeled secondary antibodies. D- Immunohistochemical detection of progesterone
receptors PR-19 and PR-20 in the cervix of mice during antepartum at term. 4 slides per animal were
stained and 6–8 animals were studied in each group. E- Trichrome staining, staining for collagen I and for
MMP-9 and in situ zymography using DQ-collagen I in cervical tissue harvested antepartum and
prepartum from mice that deliver preterm and at term. 3–4 slides per animal and 5 to 6 mice/group were
used for immunohistochemical studies. Original magnification is ×20. F- Immunohistochemical
determination of MMP-9 in cervical stromal fibroblasts at term. 4 slides per animal were stained and 6–8
animals were studied in each group. G- Immunohistochemical determination of MMP-2 in cervical
columnar epithelial and stromal cells at term during antepartum and intrapartum. 4 slides per animal were
stained and 6–8 animals were studied in each group.
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Next we investigated the presence of C5aR in End-1 cells. C5aR could not be
detected on End-1 cells by immunohistochemistry (Figure 9A). The absence of C5aR in
End-1 cells suggests that cervical columnar epithelial cells are not cellular effectors in
PTD, a complement-dependent process. Indeed, in chapter 1 we describe that
macrophages rich in C5aR are the main source of MMPs in PTD.
In addition, we found that End-1 cells express progesterone receptor (PR) at the
mRNA level. Interestingly, progesterone that inhibited MMP release from macrophages
in PTD inhibits the synthesis of MMP-2 and MMP-9 in these cells (Figure 9B).

In

agreement with these results, we were able to detect progesterone receptors (PR) 19
and 20 in mouse cervical epithelial cells by immunohistochemistry. As shown in Figure
9D, positive staining for PR-19 and PR-20 was observed in the cervical columnar
epithelium at term.
We also explored the possibility that cervical fibroblastic cells express MMPs. In
accordance to our hypothesis, we found positive staining for MMP-9 in the fibroblasts
stroma harvested antepartum in mice that deliver at term (Figure 9E). Thus, cervical
stromal fibroblastic cells can be another source of MMPs leading to cervical remodeling
and parturition at term. In addition, we measured MMP-2, another proteolytic enzyme
involved in cervical remodeling. We detected MMP-2 in the epithelium and stroma
antepartum and intrapartum at term (Figure 9F). We were not able to detect MMP-2
expression in the cervical tissue of mice that deliver preterm (data not shown).
Cervical MMPs and collagen degradation in term and preterm delivery
MMPs degrade collagen in the cervix and prepare it for dilation and delivery.3,65
Regardless the different sources of MMPs in preterm and term, remodeling of the cervix
and massive collagen degradation was observed antepartum and intrapartum in both
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term and preterm delivery (Figure 9G). Masson's trichrome (TC) staining revealed a
loose array of disordered collagen fibers in the cervix of mice that deliver preterm and
term (Figure 9G). Immunohistochemical studies with specific antibodies against mouse
collagen I showed a similar distribution pattern of collagen (Figure 9G).

Collagen

packing was disorganized, collagen fibers looked thinner and greater spacing between
fibers were observed both antepartum and intrapartum in mice that delivered at term
and preterm (Figure 9G).
Decreased density in collagen fibers was associated with increased expression
of MMP-9 (Figure 9G). In situ zymography using DQ collagen I as substrate revealed
an increase in collagenolytic activity in the cervix of mice that deliver at term and
preterm (Figure 9G).
Discussion
Is cervical remodeling in PTD caused by the same mechanism/s that cause/s
cervical remodeling at term, but are accelerated in time?

This question has been

pondered by obstetricians seeking for strategies to prevent PTD for many years. To
answer this question we investigated the initiators and cellular effectors in a mouse
model of preterm delivery and in control mice that delivered at term. In Chapter 1 we
described that complement activation plays a causative role in PTD in mice. Thus, we
sought to investigate whether complement activation also plays a role in cervical
remodeling at term. Here we found that complement activation is not involved in the
physiological process that leads to term delivery suggesting that we identified a possible
specific and selective target to prevent PTD. In addition, serum complement C3a and
C5a levels, that increased during PTD did not increase in mice that deliver at term.
That C3a and C5a increase only during PTD suggests that they can be potential
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biomarkers.

This is in agreement with several clinical studies that demonstrate a

potential role of complement split products as biomarkers of PTD.15,16,21
Recent studies in mice suggested that the mechanisms of cervical remodeling in
preterm birth is different from normal ripening at term.66,67 In one of these studies the
expression of proinflammatory genes was upregulated in preterm birth compared to
term.66 The other study demonstrated that cervical ripening preterm can be initiated by
more than one mechanism and it is not necessarily an acceleration of the physiological
process at term.67
Our data suggest that the cervical ripening at term is a non-leukocyte dependent
process. We did not find inflammatory cells in the cervix of mice with term parturition in
contrast to mice that delivered preterm. Several animal studies support our observation
that cervical remodeling at term is leukocyte-independent. Steroid 5alpha-reductase
type 1 null mice (Srd5a1−/−) that do not recruit inflammatory cells in the cervix give birth
normally suggesting that inflammatory cells are not required for term parturition.10 In
addition, granulocyte depletion with monoclonal antibodies LyG (Gr1) before birth has
no effect on the timing or outcome of parturition in mice.10 A human study emphasizes
the lack of correlation between inflammation and cervical remodeling at term. In this
study, the authors reported that inflammation-related genes did not emerge as
differentially expressed with cervical ripening.68 Even though several studies in animals
suggest that inflammatory cells do not participate in cervical ripening at term, some
human studies suggest that inflammatory cells do participate in the cervical changes in
term parturition.69,70

This discrepancy might be caused by the fact that when the

biopsies are obtained; intrapartum may overlap with postpartum and the cervical repair
process might have already started. Indeed many studies demonstrate the crucial role
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of inflammatory cells in the cervical tissue repair after delivery.10
We demonstrated in Chapter 1 that complement component C5a recruits and
activates macrophages in cervical tissue leading to cervical ripening and PTD in LPStreated mice. The absence of complement activation and generation of C5a in cervical
tissue at term might explain the absence of inflammatory cells. Despite the absence of
complement activation and inflammatory cells at term, our data demonstrate the
presence of MMPs and concomitant collagen degradation in the cervix of mice that
deliver at term and preterm. Increased expression of MMP-9, disorganized collagen
packing, thinner collagen fibers and greater spacing between fibers were observed in
both term and preterm. This suggests the existence of a common downstream pathway
shared by term and preterm cervical remodeling.
The identification of this common mechanism raises the question as to which
cells are responsible for MMP release during cervical ripening at term. It has been
established that cervical fibroblasts obtained from pregnant women are capable of
releasing MMPs in culture.71 Other studies also showed that human cervical fibroblasts
can also synthesize MMPs.42,72 In addition, Imada and collaborators demonstrated that
cervical fibroblasts from rabbits synthesize MMP-9 in culture.42

Indeed, we found

positive staining for MMP-9 in cervical fibroblastic cells in the stroma of control mice at
term.
Staining for MMP-9 and robust activity against collagen I was also observed in
the cervical columnar epithelium in mice at term. Thus, we performed in vitro studies
using End-1 cells63 (human columnar epithelial cells) to corroborate that these cells can
indeed synthesize and express MMPs. qRT-PCR studies revealed the presence of
MMP-2 and MMP-9 mRNA and in situ zymography and immunohistochemistry studies
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demonstrate the presence of active MMP-2 and MMP-9 in End-1 cells, suggesting that
columnar epithelial cells can be the source of MMPs responsible for cervical remodeling
that leads to parturition at term.
We also need to consider that cytokines secreted by the myometrium, placenta
and fetal membranes at term contribute to the release of MMPs in the cervix in the
absence of inflammatory cells.73,74

Thus, it is possible that inflammatory mediators

secreted by neutrophils infiltrating the fetomaternal interface reach the cervical stroma
and promote MMPs release.
It has been described that progesterone inhibits the release of MMPs and
collagenolysis.75,76 Interestingly, we found that progesterone inhibits the synthesis and
expression of MMP-2 and MMP-9 in End-1 cells. That progesterone inhibits MMPs
release suggests that a diminution in progesterone levels might trigger the release of
MMPs and induce cervical ripening at term. Indeed, we found that progesterone levels
drop dramatically in mice around parturition time at term, in contrast to mice that deliver
preterm. This observation suggests that progesterone withdrawal can trigger MMPs
release and subsequent parturition at term as has been suggested.64 We were not able
to detect C5aR on End-1 cells, suggesting that complement activation that is
responsible for the release of MMP-9 from macrophages in PTD is not involved in MMP
release from cervical columnar epithelial cells. Thus, we propose that progesterone
withdrawal triggers MMPs release and parturition at term. That progesterone receptors
PR-19 and PR-20 are present in cervical epithelial cells reinforces this concept.
In Figure 10 we summarize the distinct and similar features that characterize
cervical remodeling at preterm and term. 1) Preterm delivery is initiated by complement
activation while complement activation is not required for term parturition. 2) Term
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delivery was found to be non-leukocyte dependent while on the other hand PTD is
mediated by macrophages. 3) Macrophages are the source of MMPs in PTD while
cervical stromal fibroblasts and columnar epithelial cells seem to be responsible for the
production of MMPs in cervical remodeling at term. 4) The trigger for MMPs release is
C5a in PTD while our studies and other studies64 suggested that progesterone
withdrawal is the initiator of cervical ripening at term.
Figure 10. Distinct and similar features
during
preterm
and
term
cervical
remodeling. PTD is initiated by complement
activation while complement activation is not
required for term parturition. In addition term
delivery was found to be non-leukocyte
dependent while on the other hand preterm
delivery is mediated by macrophages. A
dramatic diminution in serum progesterone
levels precedes parturition at term but no
progesterone levels changes are observed in
PTD. PTD and term delivery share a common
dowsntream
pathway
characterized
by
increased MMPs release and increased
collagen degradation. The sources of MMPs in
PTD are macrophages while cervical stromal
fibroblasts and columnar epithelial cells seem to
be the source of MMPs at term. Anaphylotoxin
C5a is the trigger for MMPs release in PTD
while progesterone withdrawal seems to be the
trigger at term. In conclusion, preterm and term
cervical remodeling occur through the same
mechanism but it is initiated by different triggers
and effector cells.

Regardless the different triggers and cellular mediators, we identified a common
downstream pathway that involves MMPs release and collagen degradation in both
term and PTD.
In conclusion, preterm and term cervical remodeling occur through the same
mechanism but they are initiated by different triggers and effector cells.

Thus, we

demonstrated that preterm birth is not an acceleration of the normal physiological
cervical processes that lead to term parturition.
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This is the first study to identify the complement system as a potential biomarker
and possible specific and selective target for therapy in PTD.
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Premature cervical remodeling/ripening is believed to contribute to preterm
delivery (PTD), the leading cause of perinatal morbidity and mortality.

Despite

considerable research, the causes of term and PTD remain unclear, and there is no
effective treatment for PTD. We tested the hypothesis that complement activation plays
a role in cervical remodeling and PTD. We studied cervical remodeling at term.
We studied two mouse models of inflammation-induced PTD. The first model
was induced by vaginal administration of lipopolysaccharide (LPS)and the second one
by administration of progesterone antagonist RU486. Increased cervical C3 deposition
and macrophage infiltration and increased serum C3adesArg and C5adesArg levels
were observed in both models when compared to gestational age matched controls. A
significant increase in collagen degradation, matrix metalloproteinase 9 (MMP-9) activity
and tissue distensibility was observed in the cervix in both models. Mice deficient in
complement receptor C5a did not show increased MMP-9 activity and cervical
remodeling and did not deliver preterm in response to LPS or RU486, suggesting a role
for C5aR in the cervical changes that precede PTD. In vitro studies show that
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macrophages release MMP-9 in response to C5a. Progesterone diminished the amount
of C5aR on the macrophages surface, inhibited the release of MMP-9 and prevented
PTD. In addition, macrophage depletion also prevented cervical remodeling and PTD in
LPS-treated mice.

We found that complement activation is not required for the

physiological process that leads to term delivery in mice. Neither increased C3 cervical
deposition nor increased C3a and C5a serum levels were observed at term. In addition,
macrophages infiltration was found in PTD in contrast to term delivery were no
leukocytes were found. Despite the different role of complement and different cellular
effector cells, PTD and term delivery share a common dowsntream pathway
characterized by increased metalloproteinases (MMPs) release and increased collagen
degradation. However, different sources of MMPs were identified. Macrophages are
the source of MMPs in PTD while cervical fibroblasts and columnar epithelial cells
synthesize MMPs at term delivery. A dramatic diminution in serum progesterone levels
precedes parturition at term but not in PTD, suggesting that progesterone withdrawal
initiates cervical remodeling at term.

On the other hand, MMPs release in PTD is

triggered by C5a.
Complement inhibition and supplementation with progesterone may be good
therapeutic options to prevent this serious pregnancy complication. Preterm and term
cervical remodeling occur through the same mechanism but they are initiated by
different mediators and effector cells. That complement activation is required for PTD
but not for the physiological process that leads to term delivery, suggests that
complement is a potential specific biomarker and selective target to prevent PTD and
thus avert neonatal mortality and morbidity.
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